Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept to Present at Upcoming Investor Conferences in June
NEW YORK , May 30, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that its management will be presenting at the
View HTML
Toggle Summary Intercept to Present at Upcoming Investor Conferences in May
NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Pricing of Offerings of Common Stock and Convertible Senior Notes due 2026
NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has priced its underwritten public
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Proposed Offerings of $200 Million of Common Stock and $200 Million of Convertible Senior Notes due 2026
NEW YORK , May 08, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it is commencing an underwritten public
View HTML
Toggle Summary Intercept Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
Positive results from pivotal Phase 3 REGENERATE study of OCA in patients with liver fibrosis due to NASH New Drug Application (NDA) filing in the U.S. for OCA in NASH projected in the third quarter of 2019   Worldwide Ocaliva net sales of $51.8 million in the first quarter of 2019 representing 47%
View HTML
Toggle Summary Intercept to Announce First Quarter 2019 Financial Results on May 8, 2019
NEW YORK , May 01, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2019 financial results prior
View HTML
Toggle Summary Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH
OCA significantly improved fibrosis in patients with liver fibrosis due to NASH and demonstrated consistent efficacy across multiple histologic and biochemical parameters REGENERATE data to be presented during the Opening Ceremony of EASL NEW YORK , April 11, 2019 (GLOBE NEWSWIRE) -- Intercept
View HTML
Toggle Summary Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019
Multiple additional abstracts evaluating obeticholic acid (OCA) for the treatment of patients with progressive non-viral liver diseases to be presented at the meeting NEW YORK , April 04, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on
View HTML
Toggle Summary Intercept to Present at Upcoming Investor Conferences
NEW YORK , March 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Issues 2019 Financial Guidance and Provides Business Update
Positive topline results from pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH: the largest and first successful pivotal Phase 3 NASH study   Worldwide Ocaliva net sales of $52.9 million in the fourth quarter of 2018 and $177.8 million in the full
View HTML